Mallinckrodt To Sell BioVectra To HIG For Up To $250M
Mallinckrodt PLC on Tuesday unveiled plans to sell its BioVectra unit to an affiliate of private equity firm HIG Capital for up to $250 million, just days after the U.K.-based pharmaceutical...To view the full article, register now.
Already a subscriber? Click here to view full article